Iberdomide to boost T cells before CAR-T for multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests giving the drug iberdomide before collecting your T cells for CAR-T therapy. The goal is to make the T cells stronger so the CAR-T treatment may work better against your multiple myeloma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have multiple myeloma and are eligible for a commercial CAR-T therapy like cilta-cel or ide-cel.
- You have tried at least 2 prior treatments for your myeloma.
- You are able to go about daily activities (ECOG score 0-2).
- You must avoid pregnancy or fathering a child during and for a time after the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs (elotuzumab, iberdomide, and dexamethasone) for multiple myeloma that has come back after treatment with a type of CAR T-cell therapy called ide-cel. It aims to see if this new combination can help people who have already tried several other treatments.
This trial tests a new type of immunotherapy called Multi-CAR T cells for people with multiple myeloma that has come back or not responded to other treatments. It aims to see if these specially engineered cells can better fight the cancer.
This study tests a new type of cell therapy called CAR-T, which uses your own immune cells to fight the cancer. It is for people with multiple myeloma that has come back or not responded to at least three previous treatments.
This trial tests a new CAR-T cell therapy (called arlocabtagene autoleucel) combined with other drugs for multiple myeloma that has returned or stopped responding. It aims to find a safe and effective dose while tracking how well the treatment works.
This trial tests whether a drug called NT-I7 (a lab-made immune booster) can help people with multiple myeloma who have already received a CAR-T cell therapy called cilta-cel. It's for patients whose myeloma has come back or hasn't responded well to treatment.
This Phase 1/2 study tests a personalized CAR-T cell treatment that targets a protein called BCMA on myeloma cells. It’s designed for people with multiple myeloma who have already tried several other treatments and still have measurable disease.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.